At Life Science Washington’s annual conference, Life Science Innovation Northwest, industry veterans Hans Bishop and Steve Harr shared their expertise on building companies and discussed the future of biotech in Washington state. After working together on the founding of Juno Therapeutics, which was acquired in 2018 for more $9 billion, the pair had much to say about running a successful biotech startup.
“Remember the most important thing you’re negotiating for the partnership is not money — it’s control. Of course, you can never keep complete control. Start with the things that control the destiny of your product development,” said Hans Bishop, previous Founder, President and CEO of Juno Therapeutics.